Cancer Establishment Admits We’re Getting Overtested and Overtreated
By John Horgan,
Scientific American
| 08. 05. 2013
I’ve complained in previous columns about excessive medical testing, which leads to unnecessary treatment and drives up health care costs. Overtesting helps explain why
health-care costs for Americans are much higher than in any other nation, whereas our health ranking is low,
roughly equivalent to that of Cubans.
The medical establishment is gradually acknowledging these hard facts, as indicated by a recent article in the
Journal of the American Medical Association: “
Overdiagnosis and Overtreatment in Cancer: An Opportunity for Improvement.” The article was written by a working group formed by the American Cancer Institute last year “to develop a strategy to improve the current approach to cancer screening and prevention.”
The three authors state: “Over the past 30 years, awareness and screening have led to an emphasis on early diagnosis of cancer. Although the goals of these efforts were to reduce the rate of late-stage disease and decrease cancer mortality, secular trends and clinical trials suggest that these goals have not been met; national data demonstrate significant increases in early-stage disease, without a proportional decline...
Related Articles
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Staff, ScienceDaily | 01.05.2026
Scientists at UNSW Sydney have developed a new form of CRISPR technology that could make gene therapy safer while also resolving a decades-long debate about how genes are switched off. The research shows that small chemical markers attached to DNA
...
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...